


PERSONAL INFORMATION

Maria Trojano



Department of Basic Medical Sciences, Neurosciences and Sense Organs ,University of Bari
Piazza G. Cesare, 11, Bari, Italy



+39-0805478555



+39-3355201417



maria.trojano@uniba.it

Enterprise	University	EPR
<input type="checkbox"/> Management Level	X Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

Since 2008	Director of the Neurophysiopathology Unit at the University Hospital “Policlinico” Bari, Italy
Since 2016	Director of the Neurology “Amaducci” Unit at the University Hospital “Policlinico” Bari, Italy
Since 2018	Director of the Neurology “Puca” Unit at the University Hospital “Policlinico” Bari, Italy
Since 2018	Director of the Neurology “Ospedaliera” Unit at the University Hospital “Policlinico” Bari, Italy
From 2012 to 2018	Head of the Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari
From 2015 to 2018	Member of the Academic Senate of University of Bari

from 2012 to 2014	Main activities and responsibilities
Since 2016	President of European Committee for treatment and Research in Multiple Sclerosis (ECTRIMS)
Since 2014	Honorary Member of ECTRIMS
Since 2014	Member of the Scientific Board of the European Charcot Foundation
Since 2012	Member of the Steering Committee of the Big MS Data (BMSD) network.
Since 2000	Member of the International American/European Advisory Committee on Clinical Trials in MS
	Chair and President of the Scientific Committee of the Italian MS Registry
	Member of the Education committee of the European Academy of Neurology (EAN)
	Member of the Executive Board of Italian Neurological Society.
	Research Group Leader of Clinical Neuroimmunology Study Group of the Italian Neurological Society.
	Member of the Cerebrospinal Fluid Research Group of the World Federation of Neurology

EDUCATION AND TRAINING

1985	post-graduate degree in “Clinical Allergology and Immunology”
1981	post-graduate degree in “Neurology”
1977	Degree in Medicine

WORK ACTIVITIES
principal subjects covered or
skills acquired

Skills in the management of big-data by implementation and development of large databases (Italian MS Registry and the Big MS Data Network including five leading european MS registries which collect longitudinal data on >180,000 MS patients).
-Skills in linkage methodologies with other data sources (administrative data -; Bio-banks; cognitive decline assessment databases; Genetics banks; MRI databases and gene sequencing data sets) allowing big data analysis algorithms and development of new tools that enable physicians to deliver personalized medicine
-Design, implementation and analysis of phase IV clinical trials and real-world observational studies in neurological diseases, and basic and applied research in Neuroepidemiology and Neurochemistry/ Neuroimmunology (evaluation of biomarkers of inflammation and neurodegeneration in neurodegenerative and demyelinating diseases, in vivo and in vitro studies on molecular mechanisms of action of disease modifying drugs)

Editorial activity

Co-editor of the Multiple Sclerosis Journal (2012-2014)
Co-editor of the journal Neurological Sciences (since 2021)
Member of editorial board of NEUS

Invited presentations

More than 200 invited presentations at International (American academy of Neurology, European Academy of Neurology, European Committee for treatment and Research in Multiple Sclerosis, World Congress of Neurology)) and National Congresses.

Grants

Grants for research projects in the clinical field and translational scientific research supported by MUR, the Apulian Region, the Karolinska Institute, Sweden (Big-MS data project), MSBase Foundation, Melbourne, Australia (MSComet and MSbasis projects) and by multinational pharmaceutical companies (MS Run project, Merck Serono, Imed-web project Biogen and Novartis, Roche, Sanofi-Aventis).

ADDITIONAL INFORMATION

Total number of publications in peer-review journals: 402 (see pubmed)
Total number of citations: 16821 (Scopus)
H index: 64 (Scopus)

Publications

1. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study. Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M; Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2):e1141
2. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, Brescia Morra V, Pozzilli C, De Luca G, Inglese M, Salemi G, Maniscalco GT, Cocco E, Sola P, Lus G, Conte A, Amato MP, Granella F, Gasperini C, Bellantonio P, Totaro R, Rovaris M, Salvetti M, Torri Clerici VLA, Bergamaschi R, Maimone D, Scarpini E, Capobianco M, Comi G, Filippi M, Trojano M; Italian MS Register. Ther Adv Neurol Disord. 2021 May
3. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinva A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M. Brain. 2020 Oct 1;143(10):3013-3024.
4. Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. Liguori M, Nuzziello N, Simone M, Amoroso N, Viterbo RG, Tangaro S, Consiglio A, Giordano P, Bellotti R, Trojano M. Brain Behav. 2019 Feb;9(2):e01199.
5. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Snee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambias A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group. JAMA Neurol. 2018 Nov 1;75(11):1407-1415.
6. Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. Rosito S, Nicchia GP, Palazzo C, Lia A, Buccoliero C, Pisani F, Svelto M, Trojano M, Frigeri A. J Cell Mol Med. 2018 Feb;22(2):1236-1246
7. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Snee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group. Brain. 2017 Sep 1;140(9):2426-24
8. Prognostic indicators in pediatric clinically isolated syndrome. Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Ann Neurol. 2017 May;81(5):729-739.
9. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database. Brain. 2015 Nov;138(Pt 11):3275-86.
10. Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue. Paolicelli D, Manni A, Iaffaldano A, Tancredi G, Ricci K, Gentile E, Viterbo RG, Quitadamo SG, de Tommaso M, Trojano M. Brain Sci. 2021 Apr 9;11(4):481.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016,
I hereby express my consent to process and use my data provided in this CV
Bari, 11/02/2022